BaseSpace
Correlation Engine 2.0
Import Your Data
QuickView

FAQ

More QuickView FAQs

Back to top
Clear Search sequence regions
(e.g. Hepatitis, Pancreas, Holistic medicine, Aspirin, rs3825942, IL1A, Coagulation)
Bookmark Forward

QuickView for selumetinib (compound)


Genetic Markers

Most Correlated Genes

  1. SPRY2
  2. DUSP6
  3. XIST
  4. RBP4
  5. WIF1
Explore Genetic Markers Results

Pathway Enrichment

Most Correlated Biogroups

  1. cytosol
  2. regulation of nitrogen compound metabolic process
  3. cellular aromatic compound metabolic process
  4. heterocycle metabolic process
  5. organic cyclic compound binding
Explore Pathway Enrichment Results

Curated Studies

Most Correlated Studies

  1. Uveal melanoma cell lines reponses to selumetinib treatment
  2. Colon cancer SW480 xenografts from NOD-SCID mice treated with either selumetinib or dibenzazepine
  3. Melanoma cell line treated with MEK and PI3K/mTOR inhibitors
  4. Sonic hedgehog medulloblastoma UI226 cells sorted for CD271
  5. L1000 CMAP - Neural progenitor NPC cells treated with small molecule perturbagens
Explore Curated Studies Results

Literature

Most Relevant Literature

  1. Induction of COX-2 by feline calicivirus via activation of the MEK1-ERK1/2 pathway, and attenuation …
  2. The Synergistic Inhibitory Effect of Combining MK-2206 and AZD 6244 in MARIMO Cells Harboring a Calr…
  3. Novel LC-MS/MS method for the determination of selumetinib (AZD6244) in whole blood collected with v…
  4. The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
  5. A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade …
Explore Literature Results

Clinical Trials

Most Relevant Clinical Trials

  1. Selumetinib and Olaparib in Solid Tumors
  2. Intermittent Selumetinib for Uveal Melanoma
  3. US Selumetinib Registry
  4. Dose-escalation Study to Assess Selumetinib Safety, Tolerability and PK
  5. A Study of Selumetinib in Patients With Kaposi's Sarcoma
Explore Clinical Trials Results
  • Copyright © 2024 Illumina Inc. All rights reserved.